Clinical, kinematic and electrophysiological characterization of patients with Progressive Supranuclear Palsy and pharmacological modulation with Venlafaxine

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

DRKS

Registry ID

DRKS00025481

Enrollment

Registered

2022-02-23

Start date

2021-11-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G23.1

Interventions

Group 1: Patients with probable or possible diagnosis of Progressive Supranuclear Palsy according to the Movement Discorder Society diagnostic criteria. Dosage of the serotonin-norepinephrine-reuptak

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Sporadic onset; age at symptom onset 40 years or older; gradual progression of symptoms; signed consent form

Exclusion criteria

Exclusion criteria: Patient lacks capacity to consent; age 80 years; patient affected by diabetes mellitus, COPD, or immunosuppression (to a clinically relevant degree)

Design outcomes

Primary

Measure	Time frame
Change in neuropsychiatric/neurocognitive symtoms captured by Trail Making Test (TMT), Starkstein Apathy Scale (SAS) and Geriatric Depression Scale (GDS) after at least 4 weeks of venlafaxine administration, compared to the assessment before start of venlafaxine administration.	—

Secondary

Measure	Time frame
Parameter in objective gait analysis, pupillometry, EEG, as well as changes in the PSP-Rating scale (PSP-RS). Changes in PSP stage, PSP-Clinical Deficits Scale (PSP-CDS), Montreal Cognitive Assessment (MoCA-Test), Three-clap test, Luria-Sequence and "Verbal Fluency" from the Frontal Assessment Battery (FAB), Schwab and England Activities of Daily Living (SEADL), Clinical Global Impression-Severity Scale (CGI-s), PSP-Quality of Life Scale (PSP-QoL) and Munich Dyphagia Test (MDT). All parameter before and after venlafaxine administration of at least 4 weeks.	—

Measure

Time frame

Parameter in objective gait analysis, pupillometry, EEG, as well as changes in the PSP-Rating scale (PSP-RS). Changes in PSP stage, PSP-Clinical Deficits Scale (PSP-CDS), Montreal Cognitive Assessment (MoCA-Test), Three-clap test, Luria-Sequence and "Verbal Fluency" from the Frontal Assessment Battery (FAB), Schwab and England Activities of Daily Living (SEADL), Clinical Global Impression-Severity Scale (CGI-s), PSP-Quality of Life Scale (PSP-QoL) and Munich Dyphagia Test (MDT). All parameter before and after venlafaxine administration of at least 4 weeks.

—

Countries

Germany

Contacts

Public ContactMolly Zeitzschel

Klinik für NeurologieUniversitätsklinikum Hamburg-Eppendorf

m.zeitzschel.ext@uke.de040 74100

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026